Overview

Effects of Metformin in Heart Failure Patients

Status:
Withdrawn

Trial end date:
2018-09-10

Target enrollment:
0

Participant gender:
All

Summary

Hypothesis: In patients, who have diabetes type 2, are treated with metformin, and are admitted for HF, leads to reduced insulin requirements, as measured in units of insulin, with no negative impact on patient safety. This is a single center, prospective trial. Subjects will be randomized to initiate metformin (starting dose 500mg orally once daily up to a maximum dose of 2,500mg daily) OR be placed on insulin products for management of their type 2 diabetes mellitus.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Maya Guglin

Treatments:

Insulin
Insulin, Globin Zinc
Metformin

Criteria

Inclusion Criteria:

1. Patients > / = 18 years of age

2. Admitted to the Medicine / Cardiology Advanced Heart Failure at UK Hospital

3. Carry a diagnosis of heart failure with or without preserved ejection fraction

4. Carry a diagnosis of type 2 diabetes mellitus

Exclusion Criteria:

1. Patients <18 years of age

2. Prisoners

3. Terminal state

4. Known adverse reaction or hypersensitivity to metformin administration

5. Pregnancy

6. Pathological conditions in which metformin administration is clinically
contraindicated (Patients with acute or chronic metabolic acidosis, serum creatinine >
1.4 mg/dL in females, serum creatinine > 1.5 mg/dL in males)

7. Patients with acute cardiovascular collapse, acute myocardial infarction, septicemia

8. Patients carrying a diagnosis of type 1 diabetes mellitus

9. Patients admitted with diabetic ketoacidosis or hyperosmotic hyperosmolar state.

10. Patients who experience diabetic ketoacidosis or hyperosmotic hyperosmolar state at
any point during their hospital admission.

11. Patients admitted with a subcutaneous insulin pump

12. Patients who, at the discretion of the Medicine / Cardiology Advanced Heart Failure
service, required an endocrinology consult during their hospitalization where the
endocrine consult service is opposed to utilizing metformin in a particular patient